773 related articles for article (PubMed ID: 25406315)
21. Brain homogenates from human tauopathies induce tau inclusions in mouse brain.
Clavaguera F; Akatsu H; Fraser G; Crowther RA; Frank S; Hench J; Probst A; Winkler DT; Reichwald J; Staufenbiel M; Ghetti B; Goedert M; Tolnay M
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):9535-40. PubMed ID: 23690619
[TBL] [Abstract][Full Text] [Related]
22. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy.
Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786
[TBL] [Abstract][Full Text] [Related]
23. The Prion-Like Behavior of Assembled Tau in Transgenic Mice.
Clavaguera F; Tolnay M; Goedert M
Cold Spring Harb Perspect Med; 2017 Oct; 7(10):. PubMed ID: 27940600
[TBL] [Abstract][Full Text] [Related]
24. Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.
Marreiro A; Van Kolen K; Sousa C; Temmerman L; Vasconcelos B; Crespo-Rodriguez R; van Weering JRT; Van Dam D; De Deyn PP; Apetri A; Schoofs L; Mercken MH
BMC Mol Cell Biol; 2020 Nov; 21(1):81. PubMed ID: 33183222
[TBL] [Abstract][Full Text] [Related]
25. Ultrasensitive and selective detection of 3-repeat tau seeding activity in Pick disease brain and cerebrospinal fluid.
Saijo E; Ghetti B; Zanusso G; Oblak A; Furman JL; Diamond MI; Kraus A; Caughey B
Acta Neuropathol; 2017 May; 133(5):751-765. PubMed ID: 28293793
[TBL] [Abstract][Full Text] [Related]
26. Tau assemblies do not behave like independently acting prion-like particles in mouse neural tissue.
Miller LVC; Mukadam AS; Durrant CS; Vaysburd MJ; Katsinelos T; Tuck BJ; Sanford S; Sheppard O; Knox C; Cheng S; James LC; Coleman MP; McEwan WA
Acta Neuropathol Commun; 2021 Mar; 9(1):41. PubMed ID: 33712082
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy.
Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K
Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668
[TBL] [Abstract][Full Text] [Related]
28. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
[TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms and implications for the formation of tau oligomeric strains.
Gerson JE; Mudher A; Kayed R
Crit Rev Biochem Mol Biol; 2016; 51(6):482-496. PubMed ID: 27650389
[TBL] [Abstract][Full Text] [Related]
30. GFP-Mutant Human Tau Transgenic Mice Develop Tauopathy Following CNS Injections of Alzheimer's Brain-Derived Pathological Tau or Synthetic Mutant Human Tau Fibrils.
Gibbons GS; Banks RA; Kim B; Xu H; Changolkar L; Leight SN; Riddle DM; Li C; Gathagan RJ; Brown HJ; Zhang B; Trojanowski JQ; Lee VM
J Neurosci; 2017 Nov; 37(47):11485-11494. PubMed ID: 28986461
[TBL] [Abstract][Full Text] [Related]
31. The beta-propensity of Tau determines aggregation and synaptic loss in inducible mouse models of tauopathy.
Eckermann K; Mocanu MM; Khlistunova I; Biernat J; Nissen A; Hofmann A; Schönig K; Bujard H; Haemisch A; Mandelkow E; Zhou L; Rune G; Mandelkow EM
J Biol Chem; 2007 Oct; 282(43):31755-65. PubMed ID: 17716969
[TBL] [Abstract][Full Text] [Related]
32. Seed-competent tau monomer initiates pathology in a tauopathy mouse model.
Mirbaha H; Chen D; Mullapudi V; Terpack SJ; White CL; Joachimiak LA; Diamond MI
J Biol Chem; 2022 Aug; 298(8):102163. PubMed ID: 35750209
[TBL] [Abstract][Full Text] [Related]
33. Structure-based inhibitors of tau aggregation.
Seidler PM; Boyer DR; Rodriguez JA; Sawaya MR; Cascio D; Murray K; Gonen T; Eisenberg DS
Nat Chem; 2018 Feb; 10(2):170-176. PubMed ID: 29359764
[TBL] [Abstract][Full Text] [Related]
34. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties.
Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N
Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846
[TBL] [Abstract][Full Text] [Related]
35. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity.
Ahmed Z; Cooper J; Murray TK; Garn K; McNaughton E; Clarke H; Parhizkar S; Ward MA; Cavallini A; Jackson S; Bose S; Clavaguera F; Tolnay M; Lavenir I; Goedert M; Hutton ML; O'Neill MJ
Acta Neuropathol; 2014 May; 127(5):667-83. PubMed ID: 24531916
[TBL] [Abstract][Full Text] [Related]
36. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains.
Boluda S; Iba M; Zhang B; Raible KM; Lee VM; Trojanowski JQ
Acta Neuropathol; 2015 Feb; 129(2):221-37. PubMed ID: 25534024
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review.
Gibbons GS; Lee VMY; Trojanowski JQ
JAMA Neurol; 2019 Jan; 76(1):101-108. PubMed ID: 30193298
[TBL] [Abstract][Full Text] [Related]
38. 'Prion-like' propagation of mouse and human tau aggregates in an inducible mouse model of tauopathy.
Sydow A; Mandelkow EM
Neurodegener Dis; 2010; 7(1-3):28-31. PubMed ID: 20160454
[TBL] [Abstract][Full Text] [Related]
39. The use of mouse models to study cell-to-cell transmission of pathological tau.
Narasimhan S; Lee VMY
Methods Cell Biol; 2017; 141():287-305. PubMed ID: 28882308
[TBL] [Abstract][Full Text] [Related]
40. Tau pathology is present in vivo and develops in vitro in sensory neurons from human P301S tau transgenic mice: a system for screening drugs against tauopathies.
Mellone M; Kestoras D; Andrews MR; Dassie E; Crowther RA; Stokin GB; Tinsley J; Horne G; Goedert M; Tolkovsky AM; Spillantini MG
J Neurosci; 2013 Nov; 33(46):18175-89. PubMed ID: 24227726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
